Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
132.39
+1.42 (1.08%)
At close: Oct 3, 2025, 4:00 PM EDT
132.96
+0.57 (0.43%)
After-hours: Oct 3, 2025, 7:56 PM EDT
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$727,251
Profits / Employee
$179,935
Market Cap
256.18B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,883 | -174 | -0.23% |
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NVS News
- 2 days ago - Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance - Seeking Alpha
- 5 days ago - Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - PRNewsWire
- 5 days ago - US FDA approves Novartis' drug for skin disease - Reuters
- 6 days ago - Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S. - WSJ
- 6 days ago - Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US - GlobeNewsWire
- 6 days ago - Novartis announces commencement of tender offer to acquire Tourmaline Bio - GlobeNewsWire
- 9 days ago - Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 - GlobeNewsWire
- 11 days ago - New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies - GlobeNewsWire